Nuravax, Inc.
Publicly observedIrvine, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Irvine | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Nuravax, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | RZ48G7JQMQF5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Apr 2025Publicly observed
NIH SBIR/STTR award: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
USD 1,257,282.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2025Publicly observed
NIH SBIR/STTR award: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
USD 499,754.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.